Asherbio

Venture-backed companyasherbio.com

At Asher Biotherapeutics, we are pioneering a new approach with our cis‑targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response. With this innovation, we address an inherent shortcoming of conventional immunotherapies, which indiscriminately act on multiple cell types, resulting in suboptimal efficacy and side effects.

Rounds on record
0
More
Ask DFX about thisView relationshipsFinancing historyInvestorsOwnership and outcomes
As of · the latest observation of this company; each round carries its own date

What matters now

  1. 2 investors
    named

    2 investors on record; Third Rock Ventures, LLC. led a round.

    The investors already on the cap table shape who leads the next round.

    Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
Drawing the relationship network…

Facts

Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
0
Disclosed raised
unknownsum of rounds with a disclosed amount only
Named investors
2

Financing history

0 rounds
No dated round yet.

Who would invest

2 investors on record, then the firms most like them

Already invested

2 investors on record

Strong comparable investors

0 firms

Firms that backed two or more of the companies this company's own investors also back.

No firm backed two or more of the companies this company's investors back, so there is no comparable investor on record yet.

Broader fit

0 firms

Firms that co-invest repeatedly with this company's investors and dated a new company in the last 12 months.

No other firm co-invests repeatedly with this company's investors on record.

Ownership and outcomes

none on record
Outcome stated by investors

Listed on 2 firm portfolio pages; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.

Evidence: 2 listingseach firm's own card, as read
  • Status not stated on Third Rock Ventures, LLC. · the firm's card prints no outcome · read Sep 17, 2026 asherbio.com
    “Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel Technology Platform”
  • Status not stated on Mission Biocapital · the firm's card prints no outcome · read Sep 16, 2026 missionbiocapital.com
    “Asherbio”
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.

Credit relationships

none on record
No lender position matched to this company.

People

0 officers, 0 directors
No officer or director on record.

Timeline

0 events
No dated event on record.

Evidence

6 observations
Every observation on this company